Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005657 · ClinicalTrials.gov registry record
Genetics of Hepatitis C Virus Infection
A clinical trial of Hepatitis C and Liver Disease, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- 870
- Enrollment target
- 1
- Study location
NCT00005657 is a study of Hepatitis C and Liver Disease that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 870 participants, below the 1,882-participant average among 106 other Hepatitis C trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00005657, a study of Hepatitis C and Liver Disease, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- 870 participants
- Enrollment target
- 1
- Study location
Study Summary
The diverse clinical syndromes associated with hepatitis C underscore the multifactorial and polygenic nature of HCV infection. Both viral and host factors likely contribute to variations in infection outcome, disease susceptibility and progression, and treatment response. This protocol will focus on the immunogenetics of HCV infection. Various candidate genes, most of them related to host immune response in microbial infection, have defined genetic polymorphisms that have been associated with variable manifestations of infections including malaria, tuberculosis, leprosy, AIDS and hepatitis B. In this proposal, we plan to collect peripheral blood mononuclear cells as a source of DNA from approximately 1500 patients with HCV infection, analyze genetic polymorphisms of various candidate genes in association with viral clearance, disease progression or treatment response, and characterize the functional consequences of these polymorphisms in patients with well-defined clinical sequelae of HCV infection. We will also collect blood from patients with other forms of liver diseases (approximately 300) or normal volunteers (approximately 200) as controls. By identifying relevant host factors genetically and investigating their molecular interactions with HCV, we may gain additional insights into HCV pathogenesis and uncover new potential targets for vaccine development and treatment intervention.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 870 participants |
| Start Date | 2000-05-04 |
| Est. Completion | 2011-04-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005657
The ClinicalTrials.gov registry entry for NCT00005657 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 870 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,882-participant average among 106 other Hepatitis C trials with a reported enrollment target (54% lower). The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hepatitis C appearing as the primary indexed condition, and to 0 interventions.
NCT00005657 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00005657 about?
NCT00005657 is a clinical study titled "Genetics of Hepatitis C Virus Infection". The diverse clinical syndromes associated with hepatitis C underscore the multifactorial and polygenic nature of HCV infection. Both viral and host factors likely contribute to variations in infection outcome, disease susceptibility and progression, and treatment response. This protocol will focus o...
What is the current status of trial NCT00005657?
This trial is currently completed. The enrollment target is 870 participants. The study started on 2000-05-04. Estimated completion is 2011-04-19.
What conditions does trial NCT00005657 study?
This clinical trial studies the following conditions: Hepatitis C, Liver Disease.
Who is sponsoring clinical trial NCT00005657?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005657 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DBS TaT in Peer-assisted Telemedicine for Hepatitis C
RECRUITING · NA
-
Evaluation of Patients With Liver Disease
RECRUITING
-
The HOPE Study: Characterizing Patients With Hepatitis B and C
RECRUITING
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs
RECRUITING · NA
-
The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.